Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01419158 · ClinicalTrials.gov registry record
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
A clinical trial, sponsored by Alpha-1 Foundation.
- Completed
- Registry status
- 3,457
- Enrollment target
NCT01419158 is a clinical trial that has completed, run by Alpha-1 Foundation. The registered enrollment target is 3,457 participants.
The verdict
NCT01419158 has completed, sponsored by Alpha-1 Foundation.
- COMPLETED
- Registry status
- 3,457 participants
- Enrollment target
Study Summary
Alpha-1 antitrypsin deficiency (AATD) is considered a rare genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Recent data has suggested that AATD is not as rare as originally thought and undetected AATD may account for COPD in some patients. This study was designed to evaluate the frequency of undetected AATD in a population reporting to academic pulmonary function testing facilities who meet criteria for the diagnosis of COPD. All individuals meeting GOLD criteria for COPD will be consented and offered free testing for AATD. The results will help identify the percent of those with COPD who have undetected AATD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,457 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01419158
The ClinicalTrials.gov registry entry for NCT01419158 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpha-1 Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01419158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01419158 about?
NCT01419158 is a clinical study titled "Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)". Alpha-1 antitrypsin deficiency (AATD) is considered a rare genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Recent data has suggested that AATD is not as rare as originally thought and undetected AATD may account for COPD in some patients. This study was designed to e...
What is the current status of trial NCT01419158?
This trial is currently completed. The enrollment target is 3,457 participants. The study started on 2008-01. Estimated completion is 2010-01.
Who is sponsoring clinical trial NCT01419158?
This trial is sponsored by Alpha-1 Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.